[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628608":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":55,"centralContacts":59,"locations":67,"responsibleParty":81,"collaborators":46,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":46,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":46,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":70,"whyStopped":46,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14,20,24,28,32,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: ALN-2232","EXPERIMENTAL","Participants will be administered a single dose of ALN-2232",[13],"Drug: ALN-2232",{"label":15,"type":16,"description":17,"interventionNames":18},"Part A: Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part B: ALN-2232","Participants will be administered multiple doses of ALN-2232",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Part B: Placebo","Participants will be administered multiple doses of placebo",[19],{"label":29,"type":10,"description":22,"interventionNames":30},"Part C: ALN-2232",[13,31],"Drug: Tirzepatide",{"label":33,"type":16,"description":26,"interventionNames":34},"Part C: Placebo",[19],{"label":36,"type":37,"description":38,"interventionNames":39},"Part C: Tirzepatide","OTHER","Participants will be administered multiple doses of tirzepatide once weekly",[31],[41,47,51],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"DRUG","ALN-2232","ALN-2232 will be administered subcutaneously (SC)",[9,21,29],null,{"type":42,"name":48,"description":49,"armGroupLabels":50,"otherNames":46},"Placebo","Placebo will be administered SC",[15,25,33],{"type":42,"name":52,"description":53,"armGroupLabels":54,"otherNames":46},"Tirzepatide","Tirzepatide will be administered SC",[29,36],[56],{"name":57,"affiliation":5,"role":58},"Medical Director","STUDY_DIRECTOR",[60,65],{"name":61,"role":62,"phone":63,"phoneExt":46,"email":64},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":61,"role":62,"phone":66,"phoneExt":46,"email":64},"1-877-256-9526",[68],{"facility":69,"status":70,"city":71,"state":46,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":46},"Clinical Trial Site","RECRUITING","Mount Royal","H3P 3P1","Canada","CA",{"type":76,"coordinates":77},"Point",[78,79],-73.64918,45.51675,{"lat":79,"lon":78},{"type":82,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100628608","phase-1-a-study-to-evaluate-aln-2232-in-participants-with-obesity-100628608",false,"NCT07463846","A Study to Evaluate ALN-2232 in Participants With Obesity","A Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity","Inclusion Criteria:\n\nAll Parts:\n\n* Has a body mass index (BMI) of ≥30 kg\u002Fm\\^2 and \\\u003C40 kg\u002Fm\\^2\n* Has a hemoglobin A1c (HbA1c) \\\u003C6.5%\n\nExclusion Criteria:\n\nAll Parts:\n\n* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results\n* Receiving therapies for chronic weight management or antidiabetic medications\n\nNote: other protocol defined inclusion\u002Fexclusion criteria apply","ALL","18 Years","65 Years",{"count":94,"type":95},156,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE1","PHASE2","The purpose of this study is to:\n\n* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity\n* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity\n* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity",[102],"Obesity",[104],"siRNA, RNAi therepeutic","2026-06-10",{"date":107,"type":108},"2026-06-12","ACTUAL",{"date":110,"type":108},"2026-03-02",{"date":112,"type":95},"2028-03-02",{"name":5,"class":6},1]